AKTX - Akari Therapeutics, Plc
| Previous Close | 2.0800 |
| Open | 2.0700 |
| Bid | 2.0300 x 3000 |
| Ask | 2.0600 x 1100 |
| Day's Range | 2.0100 - 2.0700 |
| 52 Week Range | 1.5600 - 9.2000 |
| Volume | 16,884 |
| Avg. Volume | 619,693 |
| Market Cap | 32.266M |
| Beta (3Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1370 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- Zacks•5 days ago
Alexion's sBLA for Ultomiris Gets Priority Review From FDA
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
- Zacks•6 days ago
Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
- Benzinga•7 days ago
Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation
Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The secondary objective of efficacy was assessed using a standard composite scoring system. Atopic keratoconjunctivitis is a serious corneal and eye surface disease which ultimately leads to visual impairment.
- GlobeNewswire•7 days ago
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. All patients were on maximal dosage of cyclosporin, the standard of care, for at least three months prior to treatment. Improvement in the composite clinical score was seen in signs and symptoms reflecting the potential for both reduced corneal damage and improved patient comfort.
- GlobeNewswire•28 days ago
Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress
Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trialsFurther clinical data from BP and AKC trials.
- ACCESSWIRE•2 months ago
FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet
- Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks into the headlines. Recent examples include Mustang Bio (MBIO) and Akari Therapeutics (AKTX) with their respective human study results.
- GlobeNewswire•2 months ago
Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants.
- Benzinga•2 months ago
The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...
- GlobeNewswire•2 months ago
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease.
- ACCESSWIRE•2 months ago
Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs
CORAL GABLES, FL / ACCESSWIRE / April 23, 2019 / The stock market is on the verge of setting new record highs today April 23, 2019. Today we are highlighting: Akari Therapeutics, Plc (AKTX), Twitter Inc. (TWTR), Bank of America Corporation (BAC), Leafbuyer Technologies, Inc. (LBUY). Akari Therapeutics, Plc (AKTX) (Market Cap: $65.409M) traded higher on Tuesday 4/23/2019 after making a big announcement.
- Benzinga•2 months ago
Microcap Biotech Akari Rallies On Coversin Trial Results
Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for ...
- GlobeNewswire•2 months ago
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces positive initial Phase II clinical data from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.
- GlobeNewswire•3 months ago
Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will provide an update on its eye diseases program during the 2019 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) being held April 28-May 2, 2019 in Vancouver, B.C. A poster will be presented at ARVO showing Coversin’s effect in a preclinical model of autoimmune uveitis, a back of the eye orphan disease with significant unmet need.
- ACCESSWIRE•3 months ago
These Tech Stocks Could Test March Highs
CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The tech stock market is truly miraculous, mainly because the tech industry never ceases to amaze consumers as companies consistently demonstrate their ability to innovate towards the future. Over the course of the last few months, we've seen tech companies design and invent in the areas of data analytics, artificial intelligence, augmented reality, and a plethora of others. ParcelPal Technology Inc (PTNYF) (PKG), Conformis Inc (CFMS), Digital Turbine Inc (APPS), and Akari Therapeutics Plc (AKTX) represent 4 tech stocks on the rise on Monday.
- Simply Wall St.•3 months ago
What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...
- Benzinga•3 months ago
The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
- ACCESSWIRE•3 months ago
These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19)
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The future of the tech stock market directly related to the ability of companies in the tech industry to combat the growing obstacles facing humanity. In ...
- GlobeNewswire•3 months ago
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that it had a successful Type B, pre-IND meeting with the Food and Drug Administration (FDA) regarding Akari’s proposed pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
- GlobeNewswire•4 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics — New Research Emphasizes Economic Growth
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Zacks•5 months ago
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
- Zacks•5 months ago
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
- Simply Wall St.•6 months ago
What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
If you own shares in Akari Therapeutics, Plc (NASDAQ:AKTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•7 months ago
Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced recent developments and supporting data which underscore the differentiation of Coversin. “We are encouraged by new data that demonstrates the potential for improved patient comfort and ease of use. Alongside this focus on patient convenience we continue to develop Coversin as a differentiated treatment by means of its combined complement C5 and LTB4 inhibitory activity with early data readouts of our bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) trials expected in first quarter 2019,” said Clive Richardson, Interim Chief Executive Officer of Akari Therapeutics.
- GlobeNewswire•7 months ago
Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that PASylated Coversin data will be presented at the 2nd Annual 2018 Complement-Based Drug Development Summit in Boston, Mass. during an oral presentation by Andrew Luster, M.D., Ph.D., Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases Massachusetts General Hospital. Akari currently has two clinical programs open in bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) where both C5 and LTB4 are believed to be implicated.
